98%
921
2 minutes
20
Background: The COVID-19 pandemic disrupted healthcare delivery, impacting oral anticoagulants (OAC) prescribing due to increased thromboembolic risks, Vaccine-induced immune thrombotic thrombocytopenia, and guidelines favoring Direct Oral Anticoagulants (DOACs) over warfarin. Previous studies were limited to short-term analyses.
Research Design And Methods: A segmented interrupted time series analysis was conducted using the English primary care Prescription Cost Analysis data from March/2018-March/2024 to assess the impact of the first and second COVID-19 lockdowns in March and November 2020, respectively. Trends in OAC utilisation were measured using number of items per 1,000 inhabitants (NIT) and defined daily dose per 1,000 inhabitants per day (DTD).
Results: Overall, oral anticoagulants prescribing increased significantly. Pre-pandemic, both NIT (β: 0.09; 95%CI: 0.02, 0.16) and DTD (β:0.13; 95%CI: 0.09, 0.16) showed positive trends. Post-first lockdown, DTD slope declined significantly (β:-0.22; 95%CI: -0.42, -0.03). Post-second lockdown, DTD rose in both immediate level (β:1.39; 95%CI: 0.34, 2.45) and slope (β: 0.20; 95%CI: 0.0015, 0.39). Warfarin usage declined initially but rebounded, while DOACs, particularly apixaban, increased substantially (β:0.96; 95%CI: 0.11, 1.81).
Conclusions: The COVID-19 pandemic significantly impacted oral anticoagulant prescribing patterns in England. While DOAC utilisation continued to rise, warfarin use declined significantly post-first lockdown but rebounded after the second lockdown.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/17512433.2025.2473613 | DOI Listing |
Eur J Clin Invest
September 2025
Liverpool Centre for Cardiovascular Science, at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Background: Patients with atrial fibrillation (AF) with end-stage renal failure on renal replacement therapy are at high risk of stroke and bleeding, but the optimal oral anticoagulation (OAC) strategy is uncertain. To investigate the most effective OAC therapy for patients with AF on long-term dialysis.
Methods: PubMed, EMBASE and Web of Science databases were systematically searched from inception to 9 October 2024 to identify relevant studies on OAC strategy for patients with AF on long-term dialysis.
J Geriatr Cardiol
August 2025
Interventional Cardiology, Sandro Pertini Hospital, Rome, Italy.
Background: Antithrombotic strategies after percutaneous coronary interventions (PCI) in elderly patients on oral anticoagulant therapy (OAT) are debated due to the balance between ischemic and bleeding risks. Recent guidelines recommend early transitioning from triple antithrombotic therapy to dual antithrombotic therapy, but there are limited data on elderly patients.
Methods: We performed a age-specific analysis of the PERSEO Registry population aimed to compare clinical features, therapeutic strategies, and outcomes of individuals aged ≥ 80 years and < 80 years who were on OAT and underwent PCI with stent.
Front Microbiol
August 2025
Department of Allergy, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Introduction: Hepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease with a high mortality rate, and treatment methods are limited. Rivaroxaban is an oral anticoagulant. This study aimed to investigate the pharmacological effect and potential mechanism of rivaroxaban on HSOS.
View Article and Find Full Text PDFRes Pract Thromb Haemost
July 2025
Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, California, USA.
Background: Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality globally. Although direct oral anticoagulants (DOACs) have improved extended VTE treatment, the optimal dose for balancing efficacy and safety remains unclear.
Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of reduced-dose DOACs vs full-dose regimens during extended anticoagulation for VTE.
Res Pract Thromb Haemost
August 2025
Department of Pediatric Hematology, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands.
Background: Pulmonary embolism (PE) response teams are increasingly used in adult care to improve severe PE management. Understanding the epidemiology, treatment, and outcomes of severe PE in children is crucial to assessing the need for pediatric PE response teams in the Netherlands.
Objectives: To evaluate the incidence, management, and short-term outcomes of severe PE in Dutch pediatric patients.